{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:51:29Z","timestamp":1791456689384,"version":"4.3.4"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"AcademicCME"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Currently available options for managing uncontrolled and resistant hypertension are limited by safety concerns and their inability to prevent the nongenomic effects of aldosterone. Aldosterone synthase inhibitors (ASI) have emerged with Phase 3 data suggesting they provide adequate blood pressure (BP) lowering with reasonable safety profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review synthesizes the current evidence for ASIs (baxdrostat and lorundrostat) to improve BP, including pertinent pharmacologic, pharmacokinetic, effectiveness, and safety considerations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Through inhibition of the enzyme cytochrome-P450 11B2 (CYP11B2), baxdrostat and lorundrostat reduce aldosterone synthase expression, lowering aldosterone concentrations. Beyond BP-lowering effects, aldosterone synthase inhibition attenuates myocardial and vascular fibrosis promotion, endothelial dysfunction, and kidney injury. Evidence from phase 2 and 3 clinical trials in patients with uncontrolled and resistant hypertension despite being on multiple antihypertensive drugs suggests that the ASIs typically produce 5-15 mm\u00a0Hg reductions in systolic BP. While generally well tolerated, the main safety concerns include hyperkalemia, hyponatremia, hypotension, and reductions in kidney function. As mineralocorticoid receptor antagonists (MRAs) are currently recommended as the treatment of choice for resistant hypertension, comparative trials of ASIs with the MRAs are needed to better identify their place in practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The ASIs represent a promising class of antihypertensive drug classes with proven efficacy in reducing both office and ambulatory blood pressure, although studies on their comparative efficacy and safety with MRAs such as spironolactone are needed, along with evidence of cost-effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajh\/hpag077","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:41:09Z","timestamp":1783424469000},"page":"S78-S87","source":"Crossref","is-referenced-by-count":0,"title":["From bench to formulary: a pharmacological appraisal of aldosterone synthase inhibitors for uncontrolled and resistant hypertension"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2172-0931","authenticated-orcid":false,"given":"William L","family":"Baker","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, University of Connecticut School of Pharmacy , Storrs, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"2026100806025776200_hpag077-B1","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1161\/CIR.0000000000001412","article-title":"2026 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"153","author":"Palaniappan","year":"2026","journal-title":"Circulation."},{"key":"2026100806025776200_hpag077-B2","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","article-title":"Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network Meta-Analysis","volume":"2","author":"Bundy","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026100806025776200_hpag077-B3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/ajh\/hpae141","article-title":"Trends in blood pressure control among US adults with hypertension, 2013-2014 to 2021-2023","volume":"38","author":"Hardy","year":"2025","journal-title":"Am J Hypertens"},{"key":"2026100806025776200_hpag077-B4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1001\/jama.2025.25657","article-title":"Blood pressure above goal among US adults with hypertension","volume":"335","author":"Hardy","year":"2026","journal-title":"Jama."},{"key":"2026100806025776200_hpag077-B5","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1161\/HYP.0000000000000249","article-title":"AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Jones","year":"2025","journal-title":"Hypertension"},{"key":"2026100806025776200_hpag077-B6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.118.12191","article-title":"Prevalence of apparent treatment-resistant hypertension in the United States","volume":"73","author":"Carey","year":"2019","journal-title":"Hypertension."},{"key":"2026100806025776200_hpag077-B7","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension."},{"key":"2026100806025776200_hpag077-B8","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1097\/00004872-200111000-00018","article-title":"High prevalence of cardiac and extracardiac target organ damage in refractory hypertension","volume":"19","author":"Cuspidi","year":"2001","journal-title":"J Hypertens"},{"key":"2026100806025776200_hpag077-B9","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1161\/HYPERTENSIONAHA.124.23276","article-title":"Resistant hypertension and mortality: an observational cohort study","volume":"81","author":"de la Sierra","year":"2024","journal-title":"Hypertension."},{"key":"2026100806025776200_hpag077-B10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/eurjpc\/zwad066","article-title":"Apparent treatment-resistant hypertension associated lifetime cardiovascular risk in a longitudinal national registry","volume":"30","author":"Ebinger","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2026100806025776200_hpag077-B11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12882-019-1315-0","article-title":"Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES)","volume":"20","author":"Kaczmarski","year":"2019","journal-title":"BMC Nephrol"},{"key":"2026100806025776200_hpag077-B12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/ajh\/hpad084","article-title":"Characteristics and predictors of apparent treatment-resistant hypertension in real-world populations using electronic health record-based data","volume":"37","author":"Jafari","year":"2024","journal-title":"Am J Hypertens"},{"key":"2026100806025776200_hpag077-B13","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1136\/heartjnl-2022-321496","article-title":"Hypertension therapy using fixed-dose polypills that contain at least three medications","volume":"109","author":"O\u2019Hagan","year":"2023","journal-title":"Heart"},{"key":"2026100806025776200_hpag077-B14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/ajh\/hpad013","article-title":"Nonadherence is common in patients with apparent resistant hypertension: a systematic review and meta-analysis","volume":"36","author":"Bourque","year":"2023","journal-title":"Am J Hypertens"},{"key":"2026100806025776200_hpag077-B15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/jch.14788","article-title":"Adherence to antihypertensives in the United States: a comparative meta-analysis of 23 million patients","volume":"26","author":"Dean","year":"2024","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026100806025776200_hpag077-B16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1161\/HYPERTENSIONAHA.117.10662","article-title":"Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (resistant hypertension optimal treatment)","volume":"71","author":"Krieger","year":"2018","journal-title":"Hypertension."},{"key":"2026100806025776200_hpag077-B17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension."},{"key":"2026100806025776200_hpag077-B18","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet."},{"key":"2026100806025776200_hpag077-B19","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.116.07363","article-title":"Antihypertensive medications and the prevalence of hyperkalemia in a large health system","volume":"67","author":"Chang","year":"2016","journal-title":"Hypertension."},{"key":"2026100806025776200_hpag077-B20","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000237742","article-title":"Predictors of hyperkalemia risk following hypertension control with aldosterone blockade","volume":"30","author":"Khosla","year":"2009","journal-title":"Am J Nephrol"},{"key":"2026100806025776200_hpag077-B21","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/jch.12860","article-title":"Add-on use of eplerenone is effective for lowering home and ambulatory blood pressure in drug-resistant hypertension","volume":"18","author":"Eguchi","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026100806025776200_hpag077-B22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11906-019-0924-0","article-title":"Eplerenone versus spironolactone in resistant hypertension: an efficacy and\/or cost or just a men\u2019s issue?","volume":"21","author":"Manolis","year":"2019","journal-title":"Curr Hypertens Rep"},{"key":"2026100806025776200_hpag077-B23","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/01.HYP.0000201443.63240.a7","article-title":"Effects of aldosterone on the vasculature","volume":"47","author":"Schiffrin","year":"2006","journal-title":"Hypertension."},{"key":"2026100806025776200_hpag077-B24","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.1210\/en.2006-0826","article-title":"Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects","volume":"147","author":"Funder","year":"2006","journal-title":"Endocrinology."},{"key":"2026100806025776200_hpag077-B25","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1016\/S0021-9258(18)96556-7","article-title":"Aldosterone synthesis by adrenal mitochondria","volume":"241","author":"Psychoyos","year":"1966","journal-title":"J Biol Chem"},{"key":"2026100806025776200_hpag077-B26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1210\/endo-95-1-48","article-title":"Aldosterone secretion in the enucleated rat adrenal during salt retention","volume":"95","author":"Pratt","year":"1974","journal-title":"Endocrinology."},{"key":"2026100806025776200_hpag077-B27","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1210\/mend-5-10-1513","article-title":"The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex","volume":"5","author":"Curnow","year":"1991","journal-title":"Mol Endocrinol"},{"key":"2026100806025776200_hpag077-B28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mce.2003.10.011","article-title":"The regulation of aldosterone synthase expression","volume":"217","author":"Bassett","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"2026100806025776200_hpag077-B29","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jacc.2025.06.012","article-title":"Aldosterone and aldosterone modulation in cardio-kidney diseases","volume":"86","author":"Fioretti","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026100806025776200_hpag077-B30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/cvr\/cvac027","article-title":"Aldosterone and cardiovascular diseases","volume":"119","author":"Parksook","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026100806025776200_hpag077-B31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-042711-135929","article-title":"Hyperaldosteronism as a common cause of resistant hypertension","volume":"64","author":"Calhoun","year":"2013","journal-title":"Annu Rev Med"},{"key":"2026100806025776200_hpag077-B32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026100806025776200_hpag077-B33","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026100806025776200_hpag077-B34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41371-020-00426-y","article-title":"Left ventricular remodeling and dysfunction in primary aldosteronism","volume":"35","author":"Tsai","year":"2021","journal-title":"J Hum Hypertens"},{"key":"2026100806025776200_hpag077-B35","doi-asserted-by":"publisher","first-page":"e004815","DOI":"10.1161\/CIRCIMAGING.116.004815","article-title":"Cardiac remodeling in patients with primary and secondary aldosteronism: a tissue doppler study","volume":"9","author":"Cesari","year":"2016","journal-title":"Circ Cardiovasc Imaging."},{"key":"2026100806025776200_hpag077-B36","doi-asserted-by":"publisher","first-page":"105332","DOI":"10.1016\/j.phrs.2020.105332","article-title":"Aldosterone synthase inhibitors for cardiovascular diseases: a comprehensive review of preclinical, clinical and in silico data","volume":"163","author":"Lenzini","year":"2021","journal-title":"Pharmacol Res"},{"key":"2026100806025776200_hpag077-B37","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2174\/1568026611313120003","article-title":"Progress towards clinically useful aldosterone synthase inhibitors","volume":"13","author":"Cerny","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"2026100806025776200_hpag077-B38","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension."},{"key":"2026100806025776200_hpag077-B39","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation."},{"key":"2026100806025776200_hpag077-B40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","article-title":"Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2)","volume":"69","author":"Bogman","year":"2017","journal-title":"Hypertension."},{"key":"2026100806025776200_hpag077-B41","doi-asserted-by":"publisher","first-page":"e70000","DOI":"10.1111\/cts.70000","article-title":"First-in-human study evaluating safety. Pharmacokinetics, and pharmacodynamics of Lorundrostat, a novel and highly selective aldosterone synthase inhibitor","volume":"17","author":"Shimizu","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2026100806025776200_hpag077-B42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40256-024-00713-w","article-title":"Clinical pharmacokinetics and pharmacodynamics of baxdrostat","volume":"25","author":"Huston","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026100806025776200_hpag077-B43","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","article-title":"Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers","volume":"46","author":"Freeman","year":"2023","journal-title":"Hypertens Res Off J Jpn Soc Hypertens"},{"key":"2026100806025776200_hpag077-B44","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/cpdd.1371","article-title":"Results from a phase 1 study assessing the pharmacokinetics of the aldosterone synthase inhibitor baxdrostat in participants with varying degrees of renal function","volume":"13","author":"Freeman","year":"2024","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026100806025776200_hpag077-B45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40256-023-00572-x","article-title":"Results from a randomized, open-label, crossover study evaluating the effect of the aldosterone synthase inhibitor baxdrostat on the pharmacokinetics of metformin in healthy human subjects","volume":"23","author":"Freeman","year":"2023","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv"},{"key":"2026100806025776200_hpag077-B46","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"2026100806025776200_hpag077-B47","author":"CinCor Pharma, Inc","year":"2023"},{"key":"2026100806025776200_hpag077-B48"},{"key":"2026100806025776200_hpag077-B49","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1681\/ASN.0000000849","article-title":"Efficacy and safety of baxdrostat in participants with CKD and uncontrolled hypertension: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Dwyer","year":"2026","journal-title":"J Am Soc Nephrol."},{"key":"2026100806025776200_hpag077-B50","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100806025776200_hpag077-B51","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0140-6736","article-title":"Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"407","author":"Azizi","year":"2026","journal-title":"Lancet."},{"key":"2026100806025776200_hpag077-B52","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"Jama."},{"key":"2026100806025776200_hpag077-B53","doi-asserted-by":"publisher","first-page":"e104160","DOI":"10.7759\/cureus.104160","article-title":"Efficacy and safety of baxdrostat in resistant hypertension: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Wadhwani","year":"2026","journal-title":"Cureus."},{"key":"2026100806025776200_hpag077-B54","doi-asserted-by":"publisher","first-page":"11795468261436180","DOI":"10.1177\/11795468261436180","article-title":"Comparing efficacy and safety of different aldosterone synthase inhibitors for hypertension: a systematic review and network meta-analysis of randomized controlled trials","volume":"20","author":"Hassan Waseem","year":"2026","journal-title":"Clin Med Insights Cardiol"},{"key":"2026100806025776200_hpag077-B55","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100806025776200_hpag077-B56","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the launch-HTN randomized clinical trial","volume":"334","author":"Saxena","year":"2025","journal-title":"Jama."},{"key":"2026100806025776200_hpag077-B57","doi-asserted-by":"publisher","first-page":"e70155","DOI":"10.1111\/jch.70155","article-title":"Efficacy and safety of lorundrostat in uncontrolled hypertension: a systematic review and meta-analysis","volume":"27","author":"Dad","year":"2025","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026100806025776200_hpag077-B58","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/ajh\/hpaf246","article-title":"Lorundrostat for patients with uncontrolled hypertension: a systematic review with meta-analysis and trial sequential analysis","volume":"39","author":"Ribeiro","year":"2026","journal-title":"Am J Hypertens"},{"key":"2026100806025776200_hpag077-B59","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/HJH.0000000000004264","article-title":"Aldosterone synthase inhibitors for resistant or uncontrolled hypertension: a network meta-analysis of randomized clinical trials","volume":"44","author":"Elbahloul","year":"2026","journal-title":"J Hypertens"},{"key":"2026100806025776200_hpag077-B60","doi-asserted-by":"publisher","first-page":"e003535","DOI":"10.1136\/openhrt-2025-003535","article-title":"Comparative efficacy and safety of aldosterone synthase inhibitors in hypertension: a Bayesian network meta-analysis of randomised controlled rials","volume":"12","author":"Dewi","year":"2025","journal-title":"Open Heart."},{"key":"2026100806025776200_hpag077-B61","doi-asserted-by":"publisher","first-page":"102621","DOI":"10.1016\/j.jacadv.2026.102621","article-title":"Second-generation aldosterone synthase inhibitors for hypertension: a Bayesian meta-analysis of randomized trials","volume":"5","author":"Queiroga","year":"2026","journal-title":"JACC Adv"},{"key":"2026100806025776200_hpag077-B62","doi-asserted-by":"publisher","first-page":"e70181","DOI":"10.1002\/prp2.70181","article-title":"No evidence of QTc interval prolongation with baxdrostat treatment: concentration-QTc modeling assessment","volume":"13","author":"Sunn\u00e5ker","year":"2025","journal-title":"Pharmacol Res Perspect"},{"key":"2026100806025776200_hpag077-B63","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1001\/jama.2025.5129","article-title":"Spironolactone vs amiloride for resistant hypertension: a randomized clinical trial","volume":"333","author":"Lee","year":"2025","journal-title":"Jama."},{"key":"2026100806025776200_hpag077-B64","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026100806025776200_hpag077-B65","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026100806025776200_hpag077-B66","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/cvr\/cvad165","article-title":"Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis","volume":"120","author":"Tian","year":"2024","journal-title":"Cardiovasc Res"},{"key":"2026100806025776200_hpag077-B67","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/dom.15997","article-title":"Cost-effectiveness of finerenone added to standard of care for patients with type 2 diabetes-related chronic kidney disease in the United States","volume":"27","author":"Zheng","year":"2025","journal-title":"Diabetes Obes Metab"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/Supplement_1\/S78\/71667103\/hpag077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/Supplement_1\/S78\/71667103\/hpag077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:03:03Z","timestamp":1791453783000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/39\/Supplement_1\/S78\/8875939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":67,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2026,10,8]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpag077","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10,1]]}}}